Lipocine Inc., a biopharmaceutical company in the midst of clinical development, is dedicated to the pursuit of drug delivery solutions for central nervous system (CNS) disorders. The company has a variety of product candidates in their pipeline, including their lead candidate TLANDO, which offers oral testosterone replacement therapy (TRT) capabilities via testosterone undecanoate. Other notable products include LPCN 1154, aimed at treating postpartum depression, LPCN 2101 for women with epilepsy, and LPCN 1148, which offers a testosterone laurate prodrug option for decompensated cirrhosis management. In addition, Lipocine has completed Phase II trials for a variety of products such as LPCN 1144, an oral prodrug of androgen receptor modulator for non-cirrhotic non-alcoholic steatohepatitis treatment; LPCN 1111, an oral TRT product for once daily dosing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is based in Salt Lake City, Utah.